Compare EPR Properties (EPR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs McKesson Corporation — how do they compare? EPR Properties trades at $54.8 (market cap $4.17B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 26× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and McKesson Corporation for 74 Days on average.
| EPR | MCK | |
|---|---|---|
Market Cap | $4.17B | $108.46B |
Volume | 992,716 | 712,607 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $995.69 |
52-Week Low | $48.71 | $725.17 |
Typical Hold Time | 46 Days | 74 Days |
Enterprise Value | $7.68B | $115.00B |
Dividend Yield | 6.84% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $55.03, up 1.76% today, with a bearish technical signal but oversold RSI suggesting potential reversal. The REIT reported strong Q2 2026 EPS beat ($0.79 vs. $0.745 expected) and maintains a high gross margin of 91.41%. Recent news highlights its 6.5% dividend yield and diversification into theme parks and experiential properties, though 2026 net income is projected to decline to $263 million.
The stock offers value with a forward P/E of 17.44 and consensus price target of $65.50, implying 19% upside. Key risks include declining 2026 profitability, high leverage exposure, and sensitivity to interest rates. Analyst sentiment is mixed with 32% buy ratings, but institutional buying and oversold conditions support a cautious bullish outlook for income-focused investors.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
